Loading...

Stock Performance

Data Provided by Refinitiv. Minimum 15 minutes delayed.


佛跳墙2024 破解 蓝奏云

July 31, 2024 - Apellis Pharmaceuticals Reports Second Quarter 2024 Financial Results July 7, 2024 - Apellis Completes Enrollment in Two Phase 3 Studies of the Targeted C3 Therapy, Pegcetacoplan, in Patients with Geographic Atrophy (GA) July 2, 2024 - Apellis Completes Enrollment in Phase 3 Study of Pegcetacoplan in Treatment-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

佛跳墙2024 破解 蓝奏云

佛跳墙2024 破解 蓝奏云

Investor Relations:
Argot Partners
Sam Martin / Maghan Meyers
(212) 600-1902
Email: sam@argotpartners.com / maghan@argotpartners.com

Media Relations:
Tracy Vineis
(617) 420-4839
Email: media@apellis.com

佛跳墙2024 破解 蓝奏云

Sign up to receive email alerts whenever Apellis Pharmaceuticals, Inc. posts new information to the site. Just enter your email address and click Submit.

Sign Up
加速网络连接 Email Alerts RSS Feeds Contact IR
免费的翻外墙app下载  豆荚加速器官网  蓝奏云学习软件合集  翻外墙加速器下载  胡萝卜加速器下载  边缘vp  bluelayer加速器下载  日本梯子加速器